8 Penny Stocks with Biggest Upside Potential According to Analysts

6. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Share Price: $4.33

Upside Potential: 183.69%

Number of Hedge Fund Holders: 27

Ironwood Pharmaceuticals (NASDAQ:IRWD) is a gastrointestinal (GI) healthcare company that works to advance the treatment of GI diseases and redefine the standard of care administered to such patients. It develops LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). It is also an approved treatment for functional constipation in pediatric patients ages 6-17 years old.

The company is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), and several other earlier-stage assets. It is also advancing the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis, through IW-3300, a GC-C agonist. Another of the company’s treatments is CNP-104, which treats PBC, a rare autoimmune disease targeting the liver.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is making continuous progress across its strategic priorities. Prescription demand for its products is high, including an 11% increase in LINZESS in Q2. New-to-brand prescriptions are also seeing continued strength, growing 15% compared to last year. These trends make Q2 the sixth consecutive quarter of double-digit new-to-brand volume growth, highlighting the growing demand for LINZESS among healthcare providers and patients.

Apraglutide boasts a strong clinical profile, including the convenience of once weekly dosing, demonstrated high compliance rates as seen in the STARS Phase 3 study, and low incidence of both GI tolerability issues and injection site reactions. Such capabilities position it for success in the domain.

The company is also developing a solid patient service program to help boost adherence to therapy. It is advancing its launch planning, and is planning to commercialize apraglutide, once approved, through an established sales force with considerable repute among GI specialists across the US. It takes the sixth spot on our list of the top 8 penny stocks with biggest upside potential according to analysts.